Last reviewed · How we verify
NCT03476668: RTsAsMIRT
Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.
NA trial testing MIRT in Parkinson Disease in 100 participants. Completed in 1 August 2017.
1 August 2017
Quick facts
| Lead sponsor | Ospedale Generale Di Zona Moriggia-Pelascini |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 100 |
| Start date | 1 January 2017 |
| Primary completion | 1 August 2017 |
| Estimated completion | 1 August 2017 |
Drugs / interventions tested
- MIRT
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
- Attention Disturbances — all drugs for Attention Disturbances →
Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini
Who can join
Adults 40 to 85, any sex, with Parkinson Disease or Attention Disturbances. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The researchers aimed to investigate the relationship between the asymmetric dopaminergic degeneration and the attentional resources in a group of patients with Parkinson's disease (PD).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Asymmetric Dopaminergic Degeneration and Attentional Resources in Parkinson's Disease.
Ortelli P, Ferrazzoli D, Zarucchi M, Maestri R, et al · · 2018 · cited 14× · PMID 30618591 · DOI 10.3389/fnins.2018.00972
Verify or expand the search:
- PubMed search for NCT03476668
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MIRT
Trials testing the same drug.
- NCT03763955 — Effectiveness of MIRT on Hand and Finger Dexterity in PD Patients · completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Ospedale Generale Di Zona Moriggia-Pelascini trials
Trials by the same sponsor.
- NCT05714475 — Pancreas Resection for Colorectal Metastasis: Retrospective Study · unknown
- NCT05523791 — Whey Protein Supplementation in Patients With Parkinson's Disease · NA · completed
- NCT05143320 — Cognitive, Emotional and Behavioural Impairments in Patients After Sars-Cov2 Infection · completed
- NCT03616314 — Effects of Early Stepping Verticalization + FES on CIP · completed
- NCT03546244 — Evaluation of Efficacy of Musical Treadmill in PD Rehabilitation · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03476668 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ospedale Generale Di Zona Moriggia-Pelascini
- Last refreshed: 30 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03476668.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing